FirstIgnite is supporting the commercialization of the Technical University of Denmark’s new technology for selective antibody modification. The benefits of this technology include providing highly selective acylation, yields stable conjugates, and that it does not require the use of metal ions.

This technology is applicable to protein science, chemical biology, biotechnology, and biopharmaceutical production. In 2021, the global biopharmaceuticals market was worth $328 billion and is expected to grow to $853 billion by 2030.

The Technical University of Denmark’s new technology for selective antibody modification is ready for commercialization and partnership opportunities (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Technical University of Denmark team, you can schedule a time directly on their team’s calendar here.